×

Do you want to link to other websites and leave Amgen.cn?

You are now leaving Amgen China website. Amgen China takes no responsibility for the information contained on the Amgen international server or site which you will be accessing. The information you are about to access may not comply with the China regulatory environment.

×

Do you want to link to other websites and leave Amgen.cn?

You are now leaving Amgen China website. Amgen China takes no responsibility for the information contained on the Amgen international server or site which you will be accessing. The information you are about to access may not comply with the China regulatory environment.

Amgen Enters into Strategic Collaboration with Profex to Co-promote Prolia® in China Broad Market

News Releases
Nov.10, 2021

Amgen Enters into Strategic Collaboration with Profex to Co-promote Prolia® in China Broad Market

Shanghai, China, 10 November 2021– Amgen today announced that it has entered into a strategic collaboration with Profex for the co-promotion of Prolia® (denosumab, 60 mg) across certain commercial channels in China broad market. According to the agreement, Profex will be responsible for the promotion of Prolia® in China broad market, beyond the core market areas covered by Amgen's existing commercialization team.

Strategic Cooperation Signing Ceremony From Left to Right: Irene Hsu, Vice President & General Manager of Amgen China, Philip Xiao, Chief Executive Officer, Profex

Prolia® was approved by the National Medical Products Administration (NMPA) in June 2020 for the treatment of postmenopausal women with osteoporosis at high risk of fractures. This approval makes Prolia® the first and currently the only monoclonal antibody to target RANKL for the treatment of osteoporosis in China, providing an innovative therapy for improving Chinese patients' bone health management and quality of life. With the rapid aging of Chinese society, osteoporosis brings an increasingly significant disease burden. It is estimated that there are about 70 million postmenopausal women with osteoporosis in China.1

The collaboration is another important step in Amgen’s commitment to continuously accelerate the accessibility of innovative medicines to reach a broader range of patients after Prolia®'s successful inclusion into the 2020 National Reimbursement Drug List (NRDL).

"Amgen is committed to strengthening and accelerating its development in China, and answering the healthy aging challenge, through continuous exploration of new models of open cooperation," said Irene Hsu, Vice President & General Manager of Amgen China, "The strategic collaboration with Profex enables us to focus on the core markets covered by Amgen. At the same time, we will leverage Profex's capability in broad market access so our innovative product can benefit more Chinese patients faster and more efficiently, ultimately satisfying Chinese patients' unmet needs for innovative medicines."

About Prolia® (denosumab)

Prolia® is the first approved therapy that specifically targets RANKL. Prolia® is approved and marketed in over 80 markets worldwide.

Prolia® is approved in China for the treatment of postmenopausal women with osteoporosis at high risk of fractures. In postmenopausal women Prolia® significantly reduces the risk of vertebral, non-vertebral and hip fractures.

Prolia® is administered as a single subcutaneous injection of 60 mg once every six months.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit http://www.amgen.com and follow us on http://www.twitter.com/amgen.

About Amgen China

Amgen entered China in 2012 on a mission to serve patients by using science and biotechnology to improve health for Chinese patients and societies. With its headquarters in Shanghai, Amgen China is present in approximately 100 cities across the country. In China, Amgen strives to bring innovative therapies to patients in a bid to address the huge unmet needs in chronic diseases including cardiovascular disease, bone health, inflammation and nephrology.

For more information, visit www.amgen.com and follow us on Amgen China Corporate WeChat account “安进Amgen”.

About Profex

Established in 2001, Profex is a China leading specialty pharmaceutical company focusing on three areas: Dermatology & Medical Aesthetics; Orthopedics and Pain management; and Central Nervous System (“CNS”). Profex has been continuously dedicated to licensing, developing, and commercializing innovative and differentiated therapeutic products through strategic partnership with world-leading biopharma companies to benefit Chinese patients and consumers. Profex has an agile, efficient and passionate operating team, who has been proven in China market for years. They have brought expertise and commercial excellence in operation management, marketing, sales and other aspects, which stems from their profound knowledge, experience and accomplishments with MNCs. Through continuous commercial innovation, Profex has established a track record of successfully building brands and maximizing values for partners.

References

  1. 中华医学会骨质疏松和骨矿盐疾病分会. (2019). 中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布. 中华骨质疏松和骨矿盐疾病杂志, 7(12):317-318.